FDA Starts On Path To Approving Biosimilars
As it begins the lengthy process of approving the first generic versions of biologic drugs, the U.S. Food and Drug Administration has been warned by experts that it will take considerable...To view the full article, register now.
Already a subscriber? Click here to view full article